Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 ​vaccine in healthy adults aged 50 to ...

Learn how pharma company Pfizer makes money through prescription drugs, vaccines, oncology treatments, and global ...

The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9% over the same ...

Background: Although brain and heart conditions share overlapping risk factors and commonly co-occur, current cardiac and neurologic clinical guidelines are typically produced within specialty silos.

Both ImmunityBio IBRX and Moderna MRNA are biotech firms that depend largely on the successful commercialization of a single ...

With a 10.66% CAGR, Medical Biotechnology Emerges as the Cornerstone of Precision Medicine and Biopharmaceutical Innovation.Austin, United States, March 26, 2026 (GLOBE NEWSWIRE) -- Red Biotechnology ...

If approved by regulators, it could become the only Lyme disease vaccine available for people — although it would not be the ...

The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...

GSK has secured an FDA expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus.

When my father died suddenly in 2021, I raised legitimate safety concerns about mRNA vaccines. The establishment backlash was ...